CVS reports strong second quarter results and raises full year guidance
Second quarter total revenues increased to $106.1 billion. The company raised its full-year 2026 GAAP diluted EPS guidance range to $6.84-$7.04.
See the latest news and media coverage for CVS. We track all announcements, press releases, and industry mentions in real time, all in one place.
Integrated healthcare and pharmacy services company
cvshealth.comLast updated
In short: CVS faced a $2 billion Medicare-rating lawsuit, a $315 million opioid settlement and new PBM disclosure rules.
Second quarter total revenues increased to $106.1 billion. The company raised its full-year 2026 GAAP diluted EPS guidance range to $6.84-$7.04.
Adjusted operating income rose to $1.73 billion, driven by improved purchasing economics, while the company reaffirmed 2026 full-year guidance of at least $7.25 billion.
The agreement requires CVS to implement pricing and reporting changes to lower drug costs.
Revenues rose 6.2% to $100.4 billion. Adjusted EPS increased to $2.57. Full-year guidance raised for EPS and cash flow.
Insurance giant CVS Health sued the Trump administration in Georgia federal court Monday, alleging that federal quality ratings for its Medicare Advantage contracts were calculated...
CVS Pharmacy Inc. and various subsidiaries have agreed to pay $315 million to resolve a Justice Department case alleging it unlawfully dispensed medically unnecessary prescriptions...
CVS Health CVS raised its full-year outlook for the Health Care Benefits segment after reporting stronger underlying ...
CVS raises its 2026 revenue and earnings outlook, but reimbursement pressure, macro headwinds and soft front-store demand ...
Track CVS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to CVS and other trending companies.